John Gorman's deposition to Andrew Probyn Monday, May 25, 2026

Summary
I am John Grant Gorman, now 94 years of age. This deposition profiles me and my mission. My pioneering idea in 1959 for RhoGAM eliminated Hemolytic Disease of the Fetus and Newborn (HDFN) in the developed countries of the world since 1968, saving the lives of **9 million** Rh babies so far. But to my intense regret, **140,000** Rh babies are still dying annually in the Global South. Too little funding or logistic support has been generated to prevent Rh Disease there. Except for nonprofit WIRhE no one has made an effort to alleviate this desperate situation for **50 years**. There is a severe ***bystander effect***.

In 1959 I came up with a simple immunological idea that enabled Columbia University researchers and Johnson & Johnson to develop Rh Immune Globulin, the medicine which went on to eradicate Hemolytic Disease of the Newborn in developed countries, saving the lives of **9 million** Rh babies in the last **57 years**. **But**, this radically successful public health measure has not extended to **the Global South** where **9 million** Rh babies died in the same period. **140,000** Rh babies still die annually because too little funding or logistic support has been generated to prevent Rh Disease in the Global South. **3 million** Rh children are now living with cerebral palsy caused by Rh Disease. I am proposing another simple idea 57 years later, this time in pure high finance not biology, which will resolve this desperate continuing Rh crisis.

What is my new Rh idea after 57 years? It's a simple high finance deal idea that just had to be thought of. It is entirely doable in the current high finance world brimming with capital. It does not require philanthropists to donate money. Rather, it involves major investors using their influence to promote a unique high finance deal that will return billions of dollars both for them and dollar for dollar for charity. This new idea for funding WIRhE employs standard high finance dealmaking procedures on a huge scale, at a highly accelerated timeline . It will in a few weeks raise up to $**500 billion** in future royalty cash flow for charities, including **$10 billion cash** immediately for WIRhE to start on RHD eradication - **high finance with a heart**.
Even while I was an academic professor and medical researcher at Columbia and NYU medical schools, I was a serial entrepreneur, founder, co-founder, founding investor in eleven startups, I witnessed success and failure

Some background on me. I have seen some very big things happen, like RhoGAM saving millions of Rh babies. I was involved in two very successful startups: my pathology resident at Columbia started a clinical lab which grew to be Quest Diagnostics, market cap now **$17 billion**. I was a founding shareholder in Dexcom, market cap now **$18 billion**. **So, I am not fazed by the scale of the TCRA idea**. As an inveterate inventor I have more than 20 US and international patents. I spent **20 years** advising a Wall Street firm on medical companies. Interested in AI from its beginning, I worked on my Mensa AI software project for **50 years**. **I am particularly interested in inventions that require no new research and development. Just good ideas like RhoGAM**, which required no new technology. **My latest idea**: I have installed two dishwashers, and I am developing total-automated dishwashing protocols (TADP) that will remove the need to unload dishwashers in **100 million** US households and save **$100 billion** in unpaid labor in the United States, and much more in the world – enormous savings unappreciated yet by economists. Big market.

What is WIRhE, John?
WIRhE, the *Worldwide Initiative for Rh Disease Eradication*, is an active nonprofit founded by Dr. Steven Spitalnik in Rome in 2019. WIRhE has built a team of intensely dedicated members all around the world. Recently funded with seed money by the Bloomberg Foundation, WIRhE has the groundwork laid, with elaborate studies and comprehensive plans to eradicate HDN in the whole world. But this work is just the beginning - to eradicate Rh Disease, funding of **$250 million** is required annually. This sounds like a lot and it is – but I have the solution to easily raise this kind of money.

I am advocating a bold **high finance** strategy leveraging my patents on Dark Lab Automation (DLA) to create an immediate **$10 billion** endowment for WIRhE, and $**500 billion** in future royalty cash flow for charities. With the patents in strong hands, clinical labs will pay **$1 trillion** in royalties on revenues earned on lab tests run on DLA analyzers over the next 20 yeara. This unique high finance deal requires the Big 4 major clinical lab automation oligopoly: *Roche, Siemens, Abbott, and Beckman Coulter (Danaher)*, to put in place an innovative capital structure for my patent holding company TCRA. And to convince high-profile investment management firms *Morgan Stanley, Blackstone and Andreesen Horowitz*, to find investors for TCRA. I am sure that with documents and half hour one on one I could show these companies how straightforward and doable the TCRA plan is. And make clear their opportunity to save the Rh babies and make billions of dollars of profits for their own companies.

What's the bad news. John?
I do not have access to the important people who are essential for TCRA. I can't get their email addresses or phone numbers. The few I have there is no response. The phone is not picked up. My email is not answered. Communication is asynchronous. I do not have the agency to make TCRA happen.

What is agency?
Agency is the ability to get something done. It's a valuable asset. I have only **some of** the following assets that come together to create agency:

Knowledge is power **C**ompetence is power **R**esearch is power **S**ignal is power **C**apital is power **W**ealth is power **P**olitics is power **E**xperiment is power **S**kill is power **I**nfluence is power **A**ccess is power **C**losing is power **C**harisma is power **P**erspective is power **H**umility is power **C**uriosity is power **A**uthority is power **L**uck is power

What can you do about your lack of agency, John?
I have to leverage my agency, talk to people that I have access to who can give me access to more important people with agency. Like the *six degrees of separation*.

How do you plan to get access to BIG4 to explain TCRA to them, John?
One plan to gain access to BIG4 executives is to launch **the Rh Club**.

What is the Rh Club?
Members of the Rh Club will be billionaires who will take on the Rh crisis as one of their philanthropic projects. We hope that a top venture firm e.g. Andreessen Horowitz, who has ready access to billionaires, will arrange for them to become supporters of WIRhE. But, only billionaires who commit to making full use of their influence and access to BIG4 wwill be eligible to join the Rh Club. They must agree to run a concerted campaign to persuade BIG4 executives and board members to announce that BIG4 will develop and install DLA in their client clinical labs worldwide and collect the **$1 trillion** royalties from clinical labs worldwide. Even one billionaire validating the TCRA deal will remove all doubts about TCRA.

These influential billionaire Rh Club members must have BIG4 see that their DLA announcements will make BIG4's **28%** TCRA stake worth **~$100 billion** PV the same day, provide WIRhE with a **$10 billion** cash endowment, save **140,000** Rh babies annually and put **>$500 billion** in future royalties into a DAF for nonprofits. Once BIG4 understand this extraordinary deal in detail, making the DLA announcements becomes an obvious business decision. The billionaires will become members of a very exclusive **Rh Club**, accruing great kudos when their action results in saving millions of Rh babies.

This deposition is important, Andrew. When I'm gone, this document will survive. If I fail, someone will see it, take the task on, and save the Rh babies before DLA comes off patent.

What is your great new Rh idea, John?
It is a simple idea for a high finance plan that will fund WIRhE with **$10 billion** in a few weeks. And that means WIRhE will never have to fundraise again – this is a different model from most philanthropy where you're asking people for more money year after year. This way – it's done forever. It entails recruiting highly influential people into **the Rh Club**, to persuade the BIG 4 clinical lab automation manufacturers *Roche, Siemens, Abbott, and Beckman Coulter*, to announce they are embarking on best efforts to make my patented invention, DLA, Dark Lab Automation the world standard in clinical lab automation.

Who are the BIG 4?

BIG 4 are an unbreakable oligopoly of four giant manufacturers of clinical lab automation systems, we’re talking about 4 companies: *Roche, Siemens, Abbott, and Beckman Coulter (Hanover)*. These companies make the machines that complete the tests on your blood when you go to the doctor or the hospital. This powerful oligopoly is positioned to readily convince investors that only they can make DLA the standard automation system in the world’s clinical labs. Automated clinical lab analyzers will earn **$7 trillion** of recurring uncorrelated EBT in the next 20 years – clinical labs are a colossal industry – the size of the U.S. airline industry. And patented DLA can tap this existing revenue stream - to generate **~$1 trillion** in royalty cash flow over 20 years.

Once the four major Fortune 500 sized companies **announce their DLA plans**, there will be instant **gain of value** for TCRA, then projected to be valued at roughly **$300 billion**, reflecting the present value, PV, of anticipated **$1 trillion** royalties. It is planned for WIRhE to sell some TCRA shares straightaway after the BIG4’s public DLA announcements to raise an immediate **$10 billion** cash endowment. This is the same day Andrew – **the required liquid capital to fund WIRhE forever gets created that same day**. So we're not talking about doing walkathons and other standard ways charities fund themselves each year, we’re talking about solving the problem once and for all. **Done!** DLA is the only financial plan that has any chance of fully funding WIRhE. It's the Rh babies only shot.

Tell us more about Dark Lab Automation – why is this so transformational?
Dark Lab Automation or DLA is a revolutionary way of thinking about clinical lab automation. Look, I’ve been running labs and blood banks for many years, I know all the inefficiencies, and I always worked hard on figuring out how to save time and money – and make operations much faster, safer and more cost effective. Dark Lab Automation is a very simple patented idea that turns an inefficient lab into a **10X** more efficient lab, and **10X** cheaper – reducing human error and delay using artificial intelligence. The result is that the same clinical lab can process a greater menu of tests with much greater speed, using a smaller analyzer footprint. A godsend for FDA regulation compliance. It’s a real advantage if you are running a lab. I know this - when I was lab director if I had this technology and process back then, I would have loved it. And now it’s coming – and the BIG4 are the key to making it happen.

What is your driving belief for the success of startups, John?
For every successful project there must be agency for a strategic vision and a target. It’s fundamentally imagination and will. You must have knowledge, skills, drive and access to funding. But a truly economics-informed approach is more nuanced than it seems. It’s all about teamwork and having the right team. A project must be executed by people with agency who have the ability to get things done. Persuasion is key but it seems to depend on **who says it**, not what is said. There are people who have already the power today to solve the Rh crisis – they have to be on the team, they have to be in the Rh Club.

What is the strategic vision for funding WIRhE, John?

This is a simple plan that depends on the awesome agency of certain titans in Wall Street and Silicon Valley. We have a doable goal: just getting BIG 4 to make public DLA announcements that they will install DLA in the world's clinical labs. Capital is abundant. Plenty of investor's 'dry powder' is available. Existing financial resources in the world include debt, limited partner investors, private equity firms, venture capital firms, and investment banks, which collectively manage tens of trillions in assets under management (AUM). Many have discretion to direct investments for their limited partners. We are merely asking some important high finance people to use their huge agency to solve a straightforward problem **that only they can solve**. But once they act, events will flow on their own naturally.

Does your plan align with your driven beliefs?
Yes. The TCRA project will be able to create an endowment of **$10 billion** for WIRhE in the very short term. It's a totally different kind of philanthropy. Its target is instant monetization of US and international patents already allowed on DLA. TCRA is not sui generis but rather a multigenre plan comprising things done on Wall Street every day.

John, what is the discounted cash flow (DCF) analysis model for pricing stocks?
The Discounted Cash Flow (DCF) analysis model for pricing stocks estimates a company's intrinsic value by projecting its future cash flow and then discounting it back to its present value (PV). The DCF model returns a stock's calculated intrinsic value. It employs a standard formula using a discount rate that reflects the risk of future cash flows. The discount rate chosen for TCRA's stock price DCF calculation is sensitive to assumptions about the risk for TCRA's future cash flow. I believe a discount rate of **7%** is reasonable for TCRA because it is being executed by very strong highly motivated people. Which means a TCRA company **gain of value** immediately after the DLA announcements of **~$300 billion**. The TCRA company value as assessed by investors will determine how many shares WIRhE will have to sell to raise **$10 billion** cash immediately.

Who else will sell TCRA shares immediately after the BIG4 announcements, John?
By the time of the BIG4 announcement the capital structure of TCRA will be as follows: **50%** owned by nonprofits including WIRhE, **39%** owned by BIG4 and top underwriter firms, **11%** owned by early investors. All will sell **some shares** immediately after the BIG4 announcements.

How will each of BIG4 decide to make their DLA announcement?
In the weeks that follow their introduction to the plan by the Rh Club, each BIG4's corporate development executives are on with the job, each independently scrutinizing the DLA deal in detail before deciding to make the DLA announcements. Their investment in DLA is only in time and energy, as it will be fully funded upfront. BIG4 make a formidable study, reviewing and questioning every line item of the TCRA**$7 trillion** deal, every claim in the patents, each

aspect of DLA technology, and every cell and formula in the spreadsheets. They will analyze each facet of the marketing and sales program needed for DLA in large and small clinical labs. They think deeply on how their longstanding loyal client clinical labs will react to the radical technology of the future. They will tackle head-on how their clinical labs will deal with uncomfortable questions about the expensive new royalties. They must assure themselves they can sell the DLA line profitably and generate hundreds of billions of dollars of royalties over the next 20 years, and billions of cash right away, **if they just make their announcements**.

How long will it take for the venture capital firm to recruit the Rh Club and for them to have BIG4 announce their DLA projects?
We asked people with expertise in finance and the clinical lab industry to estimate how long they felt it would take our Rh club to get all BIG4 to announce their DLA programs. It just requires business decisions by four CE0s who could be fully informed of all the issues in a one hour briefing. The fastest time estimate was **2 weeks**.

What is the most important thing to understand about the financial plan. John?
The most important thing is that TCRA has two distinct phases. The first phase comprises building a rosy picture of clinical lab future royalty payments to investors and WIRhE cashing out in that picture. The second phase comprises the hard work over many years for BIG 4 to build out DLA to vastly improve the world’s clinical labs and generate **$1 trillion** in royalties. The Rh Club’s part is over. WIRhE is funded upon success of phase one.

Are WIRhE’s chances of fully funding nonexistent without TCRA, John?
Yes. **Totally nonexistent!** TCRA is the Rh babies' only shot.

How is your operating plan being received John?
It is very disappointing. It's a very straightforward plan, win-win for everybody and perfectly doable high finance. No one has come up with a reason that it is impossible or even difficult. Even some of my fellow stakeholders can't see TCRA working even though is a straightforward short term high finance plan using standard high finance practces.

We have a severe ***bystander effect***. With a few exceptions no one is willing to join me in making Rh their personal cause. Even the prospect of making millions of dollars themselves does not motivate them to take time away from their other businesses. It seems that people have difficulty believing that TCRA will work, even though it’s perfectly straightforward financially. They can’t break out from conventional thinking even though inventions are the source of the enormous wealth in the world today. I believe it’s because their brain’s System One as described in Daniel Kahneman’s wonderful book, *Thinking Fast and Slow*, people automatically decide in milliseconds that something is a no-go. And as Danny says, the brain has little interest in unlocking this fixed belief once set. Facts are relatively powerless. Yet many exciting new inventions that no one initially believed in have broken through.

What’s the bad news. John?
Despite the fact that **9 million** babies have died needlessly from Rh Disease since 1968 and one Rh baby will die every four minutes in the long future, concern for these Rh babies is not motivating even my colleagues to use their own initiatives. “It’s not my job." “Someone else will do it”. “I’m helpless anyway”.
The *bystander effect* is normal human behavior by good people. However, I believe the Big 4 CEOs can be made to realize that if they don’t make the DLA announcements, **140,000** Rh babies will continue to die every year. Hundreds of billions in philanthropic funds will remain unavailable. They will miss out on **$ 280 billion**, new equity themselves.

What’s the worse news. John?
It is the unfortunate situation I find yourself in: my current role in TCRA is DIY. It involves attention to daily operations, managing multiple asks: making spreadsheets and PowerPoint decks, managing emails, opening and closing bank accounts, paying bills, travel, incorporating companies, strategizing with company lawyers and intellectual property lawyers, developing term sheets, assigning shares to shareholders, presentations in person or on video calls. It’s not my bag. I’m a thinker not a doer, but I’m the only doer **initiating anything** right now. There’s no one else ready to pick up the CEO mantle. I am the sole leader of TCRA, acting Chairman of TCRA, acting CEO, and acting COO, sole funder - **$300,000** personal expenses so far. Others support me, but I am presently on my own handling the quotidian daily tasks of the plan. If I quit (or die) Rh babies will continue to die, **one** baby every f**our** minutes, **400** babies a day, **140,000** babies forever. And it will become impossible to pick up TCRA in the years ahead once the DLA patents have expired.

How are plans for a successor shaping up. John?
No one is stepping up. I have pleaded with people. No one wants to take on my full active leadership role. No one is willing to run TCRA. Many are willing to help, but that won’t cut it. I am **94 years old**, currently undergoing chemotherapy for prostate cancer that has metastasized to bone. When I die, unless something changes, **140,000** Rh babies will continue to die, **forever**. At this point, there is no indication that someone will assume responsibility for managing the TCRA plan, **the bystander effect in spades**. I hope I have enough time to find a successor.

Why are you giving away 90% of the royalties, John?
Plenty is enough!